•   George Lundberg, MD

    The nonprofit National Comprehensive Cancer Network (NCCN) publishes guidelines for patients to learn more about their diagnosis and their treatment options. Here is their 2022 update for peripheral T-cell lymphoma (PTCL).


  •   Emma Shtivelman, PhD

    Excerpt from Cancer Network:

    “Outcomes for patients with HER2-positive breast cancer did not differ when treated with sequential chemotherapy plus trastuzumab compared with a concurrent approach, according to a new phase III trial.

    ” ‘The effectiveness of trastuzumab with chemotherapy in the neoadjuvant setting is evident; however, the cardiac safety of trastuzumab combined with anthracyclines has been questioned,’ wrote study authors led by Kelly K. Hunt, MD, of the University of Texas MD Anderson Cancer Center in Houston.”

    Go to full article published by Cancer Network on Sep 7, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.